CPC A61K 33/30 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/198 (2013.01); A61K 31/202 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/4525 (2013.01); A61K 36/15 (2013.01); A61K 36/185 (2013.01); A61K 36/233 (2013.01); A61K 36/28 (2013.01); A61K 36/324 (2013.01); A61K 36/328 (2013.01); A61K 36/537 (2013.01); A61K 36/74 (2013.01); A61K 36/82 (2013.01)] | 4 Claims |
1. A method for treating a patient for a viral or bacterial infection and related inflammation, including Covid-19, comprising the step of administering a nutraceutical and phytochemical composition to the patient, said nutraceutical portion of the composition consisting of vitamin C, vitamin E, and zinc in any of its pyrithione, citrate, gluconate, picolinate, sulfate, acetate, or orotate forms and appropriate nutraceutical and phytochemical components for preventing or reducing viral and bacterial infections and inflammations, wherein an effective amount of anti-infectious phytochemicals and an effective amount of anti-inflammatory nutraceuticals and phytochemicals include five or more of the following anti-infectious phytochemicals:
fulvic acid; echinacea purpura extract; sage extract; uncaria tomentosa extract; Black Elderberry extract or American Elderberry extract; pomegranate extract; and Radix bupleuri extract;
two or more of the following anti-inflammatory nutraceuticals:
Omega-3 fatty acids; eicosapentanoic acid (EPA) and docosahexanoic acid (DHA}; Alpha-lipoic acid;
five or more of the following anti-inflammatory phytochemicals):
Curcumin extract with piperine; green tea extract; Boswellia serrata extract, containing three-acetyl-11-keto-beta-boswellic acid(—AKBA); resveratrol; Commiphora myrrha extract; uncaria tomentosa extract; extract of maritime pine bark; green tea extract
Cannabidiol (CBD).
|